Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
about
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyInhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticlesPhase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic indexPost-transplant immunotherapy designed to prevent cancer recurrence.Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivityThe development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Murine models for experimental therapy of pediatric solid tumors with poor prognosis.Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition.Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.Antibody-based immunotherapy in high-risk neuroblastoma.Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodyniaHistone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma.Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrowGene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.Activation of preexisting T cell clones by targeted interleukin 2 therapy.In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapyPhase II trial of hu14.18-IL2 for patients with metastatic melanoma.Immunotherapy of neuroblastoma: present, past and future.Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.Disialoganglioside directed immunotherapy of neuroblastoma.RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.Intratumoral immunocytokine treatment results in enhanced antitumor effects.Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.DNA vaccination: using the patient's immune system to overcome cancerImmunocombination therapy for high-risk neuroblastoma.Chemokine-based immunotherapy: delivery systems and combination therapies.Advances and challenges in developing cytokine fusion proteins as improved therapeutics.Immunocytokines: a review of molecules in clinical development for cancer therapy.
P2860
Q26797345-F2BECE17-AA74-4019-9933-C25EB01799D6Q27301841-203BF88F-6B33-43EE-BCE0-520B8FD0F614Q33363235-5F771E9D-B8D0-4F5D-BF8E-61E5C870EDD8Q33718131-965621E1-2A1C-48A8-A97F-5845BE52588AQ33788224-B144F640-6290-4779-B9DA-F67F982FDD84Q33997679-6AFAD684-7680-4BFA-BB33-48AD2F0D7CF2Q34038079-ABD47407-738B-4191-BE26-A53F9418DA89Q34186886-D2285D41-2DE6-4D71-8FD0-963ED0DCD2A2Q34210418-6D170314-214D-4F44-836F-AD23CF9CD849Q34465378-B0F173E9-7212-474E-BB00-05DC64A275AAQ34488726-3A640B01-56CF-41DA-B6D0-EC659A0297E8Q34725758-E59E7F33-EF39-4F0C-B40A-5E495AB56B6AQ34756781-037C593A-DAE4-4B5E-8A50-184679E0EDF7Q35031732-3B954937-5CCD-4A5C-8D62-E47D17E01EC8Q35092616-F88CFB58-57CC-4155-B61C-67FAC9D310C4Q35308393-D63C64DA-D663-4906-9409-BE10C219E448Q35556712-C739430F-D711-4B90-9A14-D31C890F8AB7Q35631506-13BA6B6D-B696-4C71-87E3-7E823B4A0327Q35747067-3625485B-7478-4343-8686-775221ACF522Q35922239-34694349-739F-420E-9EF5-0AF68CC376C5Q35953824-50C965DA-54F2-42A2-A94F-5CDF91D5F0FBQ36179663-77319471-F794-4551-B457-9F64D1D05B9EQ36219989-48A0243A-DB4F-499A-B4CC-5338ED4C3C4FQ36314064-9924BC0D-8F22-4488-A18E-269766264894Q36412879-6BBC884C-7D71-4D73-BB6E-ACB56F3E42E7Q36453273-0F6C6846-72D5-4193-B952-D0B096196BAAQ36751440-442B4E85-CA07-48DB-A702-504181B559EDQ36761416-EAE19ABA-4F14-48BD-BE01-A2C2895261CFQ36776358-C143ADC1-3AAC-4B9A-B2DA-4D2C057E4D57Q36953492-CB43E4AE-8123-4B72-862F-0B4480835197Q37038652-26BF8A56-3AC7-4062-BC4D-050793523F73Q37059790-ED92D1B8-6ADC-44F0-8D8A-4227CD151B41Q37328301-C41984A9-BA6C-4F37-9565-2570EB8935C6Q37637949-427349FB-98B6-4498-8C6A-8E0965482461Q37680218-D99483F9-82B6-4BF0-B57D-03174E4BE27CQ37825422-AF88AA92-743D-4EAA-A771-AB1ABD708116Q37991024-A4C62065-2E76-44A8-A3E8-0C839CE6B5C1Q38040509-FF697C0D-15E8-46BA-9D06-0C60A57B1870Q38088357-7686A73E-9461-4295-859F-1D27DD28A03EQ38132742-CE9EE9B1-65B1-43F1-8806-1E80A4368BA2
P2860
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
@en
type
label
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
@en
prefLabel
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
@en
P2093
P356
P1476
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
@en
P2093
P304
P356
10.1093/JNCI/89.21.1586
P407
P577
1997-11-01T00:00:00Z